Vertex Pharmaceuticals (VX1d)
FRA • Healthcare
July 27, 2026 at 11:45 UTC
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated trades on XETRA as VX1.DE and operates in biotechnology, developing and commercializing medicines centered on cystic fibrosis. In FY2025, the company generated $12.1 billion in revenue. Its marketed portfolio is led by CFTR modulators that treat defined cystic fibrosis mutation groups, and the company was founded in 1989 in Boston, Massachusetts.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Vertex Pharmaceuticals's Technical Indicators Summary
VX1d is trading near 418.9 and shows a modest buy bias driven by longer-term support and recent volume behavior. Short-term averages sit above the current price, signaling near-term pressure, while the 50/100/200-day averages remain below and provide structural support. Momentum readings are mixed—oscillators show oversold bounce signals even as short momentum is negative—and ADX around the mid-20s points to only moderate trend strength. VWAP sits slightly below the market and OBV is positive, suggesting accumulation despite limited volatility (ATR near 2%). Technical takeaway: modest buy stance amid short-term weakness but longer-term support and volume lean toward buyers.
| Indicator | Value |
|---|---|
RSI (14) | 48.54 |
Stochastic %K (14, 3, 3) | 9.89 |
CCI (20) | -94.45 |
WPR (14) | -87.50 |
Momentum (10) | -6.00 |
MFI | 13.34 |
MACD Level (12, 26) | 3.15 |
Bollinger Bands | $402.81 - $462.90 |
ATR (14) | $8.60 (2.06%) |
ADX (14) | 26.02 |
OBV | 270 |
VWAP | $412.97 |
Classic Pivot Point | $418.63 |
Fibonacci Pivot Point | $418.63 |
Simple Moving Averages | $388.21 - $432.86(5 indicators) |
Exponential Moving Averages | $386.67 - $423.01(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
VX1d eased upward and sits 0.40% over yesterday’s close of 420.80. An earnings catalyst is just ahead in 7 days (3 August) for VX1d.
Trading Volume
Below 10d avg (50)
2
vs S&P 500 Today
Moderate Outperformance
+0.35%
52-Week Position
Upper range
72.6%
Updated: July 27, 2026 at 11:31 UTC
Quote Summary
VX1d Headlines
Vertex to buy Crinetics for $10 billion
July 6, 2026
Biotech ETFs Flash Classic Reversal Signal
April 1, 2026
Executives File New SEC Form 144 Sales
February 27, 2026